Cargando…
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs)— either as monotherapy or in combination...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157337/ https://www.ncbi.nlm.nih.gov/pubmed/35640927 http://dx.doi.org/10.1136/jitc-2021-003956 |
_version_ | 1784718617483411456 |
---|---|
author | Govindan, Ramaswamy Aggarwal, Charu Antonia, Scott J Davies, Marianne Dubinett, Steven M Ferris, Andrea Forde, Patrick M Garon, Edward B Goldberg, Sarah B Hassan, Raffit Hellmann, Matthew D Hirsch, Fred R Johnson, Melissa L Malik, Shakun Morgensztern, Daniel Neal, Joel W Patel, Jyoti D Rimm, David L Sagorsky, Sarah Schwartz, Lawrence H Sepesi, Boris Herbst, Roy S |
author_facet | Govindan, Ramaswamy Aggarwal, Charu Antonia, Scott J Davies, Marianne Dubinett, Steven M Ferris, Andrea Forde, Patrick M Garon, Edward B Goldberg, Sarah B Hassan, Raffit Hellmann, Matthew D Hirsch, Fred R Johnson, Melissa L Malik, Shakun Morgensztern, Daniel Neal, Joel W Patel, Jyoti D Rimm, David L Sagorsky, Sarah Schwartz, Lawrence H Sepesi, Boris Herbst, Roy S |
author_sort | Govindan, Ramaswamy |
collection | PubMed |
description | Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs)— either as monotherapy or in combination with other ICIs or chemotherapy—have demonstrated benefits in first-line therapy for advanced disease, the neoadjuvant and adjuvant settings, as well as in additional thoracic malignancies such as small-cell lung cancer (SCLC) and mesothelioma. Challenging questions remain, however, on topics including therapy selection, appropriate biomarker-based identification of patients who may derive benefit, the use of immunotherapy in special populations such as people with autoimmune disorders, and toxicity management. Patient and caregiver education and support for quality of life (QOL) is also important to attain maximal benefit with immunotherapy. To provide guidance to the oncology community on these and other important concerns, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). This CPG represents an update to SITC’s 2018 publication on immunotherapy for the treatment of NSCLC, and is expanded to include recommendations on SCLC and mesothelioma. The Expert Panel drew on the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for lung cancer and mesothelioma, including diagnostic testing, treatment planning, immune-related adverse events, and patient QOL considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers using immunotherapy to treat patients with lung cancer or mesothelioma. |
format | Online Article Text |
id | pubmed-9157337 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-91573372022-06-16 Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma Govindan, Ramaswamy Aggarwal, Charu Antonia, Scott J Davies, Marianne Dubinett, Steven M Ferris, Andrea Forde, Patrick M Garon, Edward B Goldberg, Sarah B Hassan, Raffit Hellmann, Matthew D Hirsch, Fred R Johnson, Melissa L Malik, Shakun Morgensztern, Daniel Neal, Joel W Patel, Jyoti D Rimm, David L Sagorsky, Sarah Schwartz, Lawrence H Sepesi, Boris Herbst, Roy S J Immunother Cancer Position Article and Guidelines Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs)— either as monotherapy or in combination with other ICIs or chemotherapy—have demonstrated benefits in first-line therapy for advanced disease, the neoadjuvant and adjuvant settings, as well as in additional thoracic malignancies such as small-cell lung cancer (SCLC) and mesothelioma. Challenging questions remain, however, on topics including therapy selection, appropriate biomarker-based identification of patients who may derive benefit, the use of immunotherapy in special populations such as people with autoimmune disorders, and toxicity management. Patient and caregiver education and support for quality of life (QOL) is also important to attain maximal benefit with immunotherapy. To provide guidance to the oncology community on these and other important concerns, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). This CPG represents an update to SITC’s 2018 publication on immunotherapy for the treatment of NSCLC, and is expanded to include recommendations on SCLC and mesothelioma. The Expert Panel drew on the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for lung cancer and mesothelioma, including diagnostic testing, treatment planning, immune-related adverse events, and patient QOL considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers using immunotherapy to treat patients with lung cancer or mesothelioma. BMJ Publishing Group 2022-05-31 /pmc/articles/PMC9157337/ /pubmed/35640927 http://dx.doi.org/10.1136/jitc-2021-003956 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Position Article and Guidelines Govindan, Ramaswamy Aggarwal, Charu Antonia, Scott J Davies, Marianne Dubinett, Steven M Ferris, Andrea Forde, Patrick M Garon, Edward B Goldberg, Sarah B Hassan, Raffit Hellmann, Matthew D Hirsch, Fred R Johnson, Melissa L Malik, Shakun Morgensztern, Daniel Neal, Joel W Patel, Jyoti D Rimm, David L Sagorsky, Sarah Schwartz, Lawrence H Sepesi, Boris Herbst, Roy S Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma |
title | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma |
title_full | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma |
title_fullStr | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma |
title_full_unstemmed | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma |
title_short | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma |
title_sort | society for immunotherapy of cancer (sitc) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma |
topic | Position Article and Guidelines |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157337/ https://www.ncbi.nlm.nih.gov/pubmed/35640927 http://dx.doi.org/10.1136/jitc-2021-003956 |
work_keys_str_mv | AT govindanramaswamy societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT aggarwalcharu societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT antoniascottj societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT daviesmarianne societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT dubinettstevenm societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT ferrisandrea societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT fordepatrickm societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT garonedwardb societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT goldbergsarahb societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT hassanraffit societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT hellmannmatthewd societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT hirschfredr societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT johnsonmelissal societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT malikshakun societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT morgenszterndaniel societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT nealjoelw societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT pateljyotid societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT rimmdavidl societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT sagorskysarah societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT schwartzlawrenceh societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT sepesiboris societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT herbstroys societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma |